ArticleGynecologic oncology2014

Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.

Monica N Schointuch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.